Predicting the progression of a patient's cancer can often help an oncologist determine the Goldilocks course of treatment — not too harsh, not too light, but just right. Researchers at the Einstein Medical Center in Pennsylvania are using a gene test from Genomic Health to help them determine if women with ductal carcinoma in situ need aggressive treatment or not, reports USA Today's Liz Szabo.
Precisely
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.